Capsida
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
290 Rancho Conejo Blvd, Thousand Oaks, C...Website
www.capsida.comRevenue
$10 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Capsida
Founded in 2019, based out of Thousand Oaks, CA, Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform.Explore more
Capsida Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capsida your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Capsida
Check out if Capsida is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Capsida has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Capsida launches new products
Funding: Get notified immidiatlly once Capsida has new funding data
Capsida, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Capsida had a recent Job posting/layoffs
Earning: See what the market has to say on Capsida recently announced quarterly report
Recommended Actions
Find VP level buyers at Capsida
Find more new buyers
Compare Similar Companies to Capsida
Compare insights from companies similar to Capsida, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Capsida is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Capsida is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Capsida.
Capsida financials insights
Gather financial insights about Capsida, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Corporate Investment
$90M
Series A
$50M
Capsida Tech Stack
A closer look at the technologies used by Capsida
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Project
Commentary
Person-Based
Business Intelligence, Analytics & Insights, Social Media, Communications, Public Relations, Social Media Marketing
Capsida News & Media
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics (“Capsida”) today announced the presentation of new non-human primate (NHP) GLP toxicology data for CAP-002, its wholly owned first-in-class, intravenously (IV) administered investigational gene therapy for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). These data were the foundation for the Investigational New Drug (IND) application for CAP-002 that was recently cleared by the U.S. Food and DruCapsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-002, its wholly owned first-in-class, intravenously (IV) administered gene therapy to enter clinical trials for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). This is the first program entering a human clinical trial utilizing an IV-administered, blood brainCapsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics (“Capsida”) today announced it will present new data on its positive progress across its wholly owned pipeline, proprietary capsid engineering, and manufacturing in seven scientific presentations accepted at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13-17, 2025, in New Orleans and virtually. Capsida will deliver three oral presentations highlighting advances in Capsida’s piCapsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson's Disease Associated with GBA Mutations (PD-GBA)
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25. THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new data...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Capsida
Sign Up For FreeTo access detailed company insights
Founded in 2019, based out of Thousand Oaks, CA, Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform.... Read More
